Alimera Sciences (NASDAQ:ALIM) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a report published on Friday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

ALIM has been the subject of a number of other reports. HC Wainwright cut shares of Alimera Sciences from a buy rating to a neutral rating and set a $6.00 price objective for the company. in a research note on Tuesday, June 25th. Alliance Global Partners reiterated a neutral rating on shares of Alimera Sciences in a report on Tuesday, June 25th. Finally, Maxim Group reissued a hold rating on shares of Alimera Sciences in a report on Tuesday, June 25th.

Alimera Sciences Stock Down 0.2 %

Alimera Sciences stock opened at $5.55 on Friday. Alimera Sciences has a fifty-two week low of $2.61 and a fifty-two week high of $5.65. The firm has a market capitalization of $301.81 million, a price-to-earnings ratio of -3.54 and a beta of 1.25. The stock’s fifty day moving average is $5.56 and its two-hundred day moving average is $4.31. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.62 and a current ratio of 2.79.

Alimera Sciences (NASDAQ:ALIM) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02). Alimera Sciences had a negative return on equity of 33.70% and a negative net margin of 14.74%. The business had revenue of $27.00 million during the quarter, compared to analysts’ expectations of $25.76 million. Analysts predict that Alimera Sciences will post -0.13 EPS for the current fiscal year.

Hedge Funds Weigh In On Alimera Sciences

Institutional investors have recently modified their holdings of the company. Fifth Lane Capital LP purchased a new stake in Alimera Sciences in the 1st quarter worth approximately $83,000. Vanguard Group Inc. boosted its holdings in shares of Alimera Sciences by 61.1% during the first quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock worth $4,077,000 after purchasing an additional 396,506 shares during the last quarter. Hillsdale Investment Management Inc. purchased a new stake in shares of Alimera Sciences in the first quarter valued at $169,000. Ancora Advisors LLC acquired a new position in Alimera Sciences in the first quarter valued at $915,000. Finally, Deltec Asset Management LLC purchased a new position in Alimera Sciences during the second quarter worth about $690,000. Institutional investors and hedge funds own 99.83% of the company’s stock.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).